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Background: Optimal selection of blood donors is of paramount importance in ensuring the safety of blood
products. The current selection process is concerned principally with the safety of the blood donor and the safety
of the patient that receives the blood. Recent evidence suggests that the characteristics of the donor may affect
transfusion outcomes for the recipient.
Methods: We will conduct a systematic review of the association between major blood donor characteristics and
red blood cell (RBC) transfusion outcomes. The primary objective is to assess the association of blood donor
characteristics and the risk of adverse short-term and long-term clinical outcomes after RBC transfusion. We will
search MEDLINE, EMBASE, Cochrane Central databases, as well as perform manual searches of top transfusion medical
journals for prospective and retrospective studies. Study characteristics will be reported and the methodological
quality of studies will be assessed. When appropriate, we will provide pooled odds ratio with 95% confidence
intervals of the effect estimates, study clinical heterogeneity using pre-defined sensitivity and subgroup analyses,
and study statistical heterogeneity using the I2 test.
Discussion: The results of this systematic review will provide an evidence base regarding the potential clinical
effects of donor characteristics on transfusion recipients to better guide policy and clinical practice. The evidence
gathered from this review will also identify strengths and weaknesses of published studies regarding donor
characteristics and transfusion outcomes and will identify knowledge gaps to inform future research in this field of
transfusion medicine.
Trial registration: PROSPERO Registration Number: CRD42013006726Background
Transfusion of blood products is a necessary, lifesaving
intervention. More than 85 million units of red blood cells
(RBCs) are collected and transfused every year worldwide
[1]. RBCs are given to increase oxygen delivery to tissues
and used across a variety of medical and surgical situa-
tions. For instance, approximately 30% of critical care pa-
tients, and more than 50% of cardiac surgery patients, will
receive a transfusion during their hospital stay [2,3].
Importantly, the use of RBC transfusion is not without
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unless otherwise stated.can be reduced by a variety of measures, including
donor questionnaires that assess risk, infectious disease
blood screening, and other quality measures already
implemented by blood agencies [4,5]. An important aim
of current measures in reducing risks for patients is to
better select blood donors. These measures have been
shown to be efficient in improving transfusion outcome.
For example, better screening of donors and microbio-
logical testing of the blood products have led to the re-
duction of transfusion-related infections as low as 1 in 8
million for HIV, 1 in 6.7 million for hepatitis C virus and
1 in 1.7 million for hepatitis B virus [6]. More recently,
female sex, a history of pregnancy and the presence of
anti-leukocytes antibodies in blood products have been
associated with the risk of transfusion-related acute lungLtd. This is an Open Access article distributed under the terms of the Creative
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after transfusion. These findings have led directly to suc-
cessful interventions (collection of male-only plasma for
example), with a subsequent decrease in the occurrence
of transfusion-related acute lung injury in Canada [7,8].
Finally, red blood cell units have important biologic vari-
ability due to the fact that each unit is collected from an
individual volunteer donor. This variability and the vari-
ability of interactions between donor and recipient may
affect the clinical efficacy and safety of a blood transfusion.
Although many measures are undertaken to select blood
donors based on their clinical characteristics, there are no
systematic reviews evaluating the impact of donor charac-
teristics on transfusion recipient morbidity and mortality.
Limitations of evidence
Notably, the medical literature is extensive regarding the
impact of donor characteristics on outcome of solid organ
and bone marrow transplanted patients. These characteris-
tics are used routinely to determine if a specific organ may
be suitable for transplantation. Patient characteristics are
also used to select the best recipient for a particular organ
and to optimize follow-up of transplanted patients when
some characteristics from the donor are not optimal.
In contrast, when it comes to blood transfusion (which
is similar to the transplantation of a different organ)
there is a paucity of data regarding the impact of donor
characteristics on outcome. We suggest the following
evidence to support our rationale to examine the effect of
donor characteristics on transfusion outcomes: 1) literature
for solid organ transplantation demonstrates the effect of
age and gender on recipient outcomes [9-13]; 2) there are
immunological modifications that are associated with age
such as the increase in memory T cells from naïve T cells
[13]; 3) decreased tolerance of the immune system with age
[13]; 4) in platelet transfusion, allergic transfusion reactions
seem to be associated more with recipient and donor factors
than with product attributes [14]; and 5) immunological
phenomena in the donor such as the anti-leukocyte anti-
bodies (anti-human-leukocyte antibodies or anti-neutrophil
antibodies) that occur after pregnancies (for example gender
effect on transfusion-related acute lung injury) and the suc-
cessful interventions (collection of male-only plasma) to re-
duce the occurrence of adverse events and improve the
safety of RBC transfusion [7,8]. The biological plausibility,
clinical evidence in solid organ transplant, and current pol-
icies that select donors based on their characteristics man-
dates a systematic review to provide a rigorous evidence
base for the potential effects of donor characteristics and
their impact on outcome.
Research objectives
The primary objective of this systematic review is to
evaluate the association of blood donor characteristics(for example age, gender, ABO blood type) and the risk
of adverse short-term and long-term clinical outcomes
after RBC transfusion in recipients. Our secondary objec-
tives are: 1) to assess the risk of bias of studies informing
current policies for selection of blood donors on their
characteristics; and 2) to identify knowledge gaps and po-
tential future research directions in the selection of blood
donors based on their characteristics.
Methods/Design
The methods to be used for this systematic review will fol-
low strict methodological standards based on the Cochrane
Collaboration recommendations [15]. Our approach will
include, in addition to our research goals and objectives,
a thorough process for study identification and selection,
a descriptive quality assessment of included studies, and a
data analysis, and interpretation.
Search strategy
We will develop a comprehensive and systematic search
strategy with an information specialist trained in the
conduct of systematic reviews. We will use MeSH
(or EMTREE equivalent) terms in addition with free
text terms representing the included population, exposure
to RBC and donor characteristics and outcomes, to be
sensitive and inclusive (Additional file 1). We will search
MEDLINE database, EMBASE database and Cochrane
Central databases (that include the Cochrane Database
of Systematic Reviews, the Cochrane Central Register of
Controlled Trials, the Cochrane Methodology Register,
the Database of Abstracts of Reviews of Effects, the Health
Technology Assessment Database and the NHS Economic
Evaluation Database) from inception and updated until au-
thors are ready for final abstraction of selected references.
Our search strategy will have no language restrictions.
Reference lists of published narrative reviews, system-
atic reviews, and eligible studies will be searched for
additional references. We will finally perform manual
screening of published articles since the year 2000 of five
journals in the field of transfusion medicine, according to
the 2012 Thomson Reuters’ impact factor and from expert
opinion of the most clinically relevant journals in the field
(Blood, Transfusion Medicine Review, British Journal of
Hematology,Vox Sanguinis and Transfusion).
Study screening and inclusion
Using the results of our comprehensive search strategy,
we will obtain title and abstract from all references. If an
abstract is not available, full text will be obtained unless
the title is clearly irrelevant. From abstracts and titles, a
screening process will be performed by two independent
reviewers for each reference using the inclusion and ex-
clusion criteria below. Full text copies of relevant reports
will then be obtained for independent analysis by two
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reviewer will then collect the required data from selected
studies using a piloted electronic form. Disagreements
will be resolved by consensus and by consultation with a
third independent reviewer when needed.
Inclusion criteria for review
Study type
We will include both observational studies (including
cross-sectional and cohort studies) and interventional
studies. Our aim in synthesizing all available evidence
is to provide not only estimates of association but also
the clinical and methodological quality of the evidence
and identify important gaps in the evidence.
Population
The aim of RBC transfusions is to improve oxygen delivery
to tissues. Such is the case for patients with active bleeding
of any cause, or for patients with subacute or chronic
anemia, including patients with cancer, patients hospitalized
in intensive care units or patients with terminal renal fail-
ure. For this systematic review, the population of interest
will be patients (in-hospital or outpatient) with any medical
condition requiring at least one RBC unit. There will be no
age restriction for this systematic review.
Intervention (exposure)
RBC transfusion accounts for the major part of blood
supply organizations blood product manufacture activities
[16-18]. A RBC unit comes from a unique donor, whereas
plasma and platelets may come from several different do-
nors and be pooled into a single unit before transfusion.
Since RBC products are the most commonly used blood
product, have the most important societal and clinical out-
reach, and a single unit comes from a single donor, our re-
view will focus on RBC transfusions only. We will include
all studies evaluating donor characteristics, focusing
on age, sex and blood group that assess at least one
pre-defined donor characteristic and its effect on recipients.
Outcomes, setting and timeframe
The primary outcome for this review is mortality. However,
to better appraise the impact of donor characteristics
on outcome, we will not restrict outcomes in the
search strategy. Rather, the search strategy will capture
any clinical or surrogate outcomes related to donor
characteristics. We will not use a limit for year of pub-
lication in this review.
Exclusion criteria
 Studies in which the study population includes
non-transfused patients and from which it is impossible
to obtain results for transfused patients. Studies with no measure of association between
donor characteristics and transfusion outcome.
 Case reports (≤2 cases) and case series.
 Duplicates or ‘sub-cohorts’ of already published
cohorts.
Analysis plan
A descriptive analysis of all included studies will be first
performed in tables and text form. Clinical, demographic,
and methodological quality characteristics and results
within study will be reported and discussed. An in-depth
discussion of heterogeneity between studies will be pro-
vided where applicable. We will perform meta-analyses of
suitable studies and provide a discussion of the results.
Study characteristics
Each study will be categorized as observational or interven-
tional. Interventional studies will be categorized as random-
ized or non-randomized, and observational studies will be
further categorized as cohort (retrospective or prospective)
and case-control studies. Further major characteristics
of the study design will be reported. We will describe
the population studied including the total number of
patients, clinical characteristics, the number of transfused
patients, the blood products transfused with the proportion
for each blood product, the characteristics of included
patients (age, gender and reasons for transfusion), and
inclusion and exclusion criteria.
Risk of bias
We expect that most of included studies will be obser-
vational. Meta-analyses of observational studies may be
more prone to bias [16]. Particular care will be taken to
adequately investigate the methodological and clinical
risk of bias before proceeding with the meta-analysis.
Methodological quality assessment
The methodological quality of the included studies in
this systematic review will be evaluated by two inde-
pendent reviewers using the Downs and Black tool for
assessing risk of bias [15]. The Downs and Black tool is the
updated evidence-based quality tool for use in assessing
risk of bias when including non-randomized studies in
systematic reviews of interventions recommended by the
Cochrane Collaboration [16]. Specific coding instructions
adapted for this review will be included for reviewers and
will be piloted prior to implementation on all selected ref-
erences. Overall and study-specific appraisal of methodo-
logical strengths and weaknesses will be reported.
Clinical risk of bias and effect modification
There is a high risk of clinical heterogeneity introduced by
the many potential indications of transfusions of RBCs.
The studied populations will most likely be very different
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equately define the clinical characteristics of the transfused
patients and the indication for transfusion and if possible
contact authors for further clarification. Sensitivity analyses
will be performed to evaluate impact of these differences.
Changes in manufacture and storage policies, as well
as donor inclusion and exclusion criteria changed signifi-
cantly over the years. For example, age limits for blood
donation have increased in many jurisdictions [17,18],
preservative solutions used for RBCs have changed and
the manufacture process has been modified by performing
universal leukoreduction on RBC products [1,4]. In cases
where the exact donor inclusion criteria and manufacture
characteristics are not reported, we will attempt to contact
authors for further details.
Primary analysis
For our primary outcome of mortality, we will provide
for each of the donor characteristics the reported number
of alive and dead patients for exposed and non-exposed
patients. We will also report the number of patients lost
to follow-up to assess the completeness of the reported
events. We will collect adjusted mortality risk as odds
ratios or relative risks if reported. When appropriate, we
will provide pooled effect estimates as pooled log-odds
ratios with 95% confidence intervals using a random-
effects modeling approach. The results will be presented
in tables and forest plots. Continuous endpoints will be
described and pooled using weighted means ratios with
random-effects modeling. Statistical heterogeneity will
be reported using the I2 test with 95% confidence intervals.
If the number of studies included is sufficient (≥10), we will
investigate the presence of publication bias using funnel
plot techniques.
Planned subgroup analyses to explain clinical heterogeneity
Given that our study has the potential, by design, to include
different populations that have received RBC transfusions,
clinical heterogeneity is expected. To explore clinical and
statistical heterogeneity, assuming that pooling of data is
possible and appropriate, we will report pooled log-odds
ratio for the following subgroups: 1) adults ≥18 years
versus mixed children/adults, only children versus only
adult, and we will consider subgroups among children
(<1 month and neonates versus other children <18 years;
2) hospitalized patients versus outpatient transfused pa-
tients; 3) patients transfused in the intensive care units
versus hospitalized but not in the intensive care units; 4)
significant changes in donor inclusion criteria or manu-
facture strategy; 5) surgical versus medical population
(≥75% of included patients); 6) patients with acute versus
chronic anemia; and 7) continent where the studies were
conducted (North America, South America, Europe, Asia,
Australia and Oceania).Planned sensitivity analyses to investigate impact of
study design
We will conduct subgroup analyses to explore and explain
heterogeneity in effects sizes and investigate robustness of
our results. It is impossible to identify all potential sensi-
tivity analyses, but we can pre-specify important sensitivity
analyses based on the Downs and Black tool for the qual-
ity assessment of randomized and non-randomized stud-
ies that will have to be performed: selection bias,
comparability of groups, and appropriateness of out-
come assessment (blinded, length of follow-up, complete
follow-up) [15].
Quality of evidence
The quality of the evidence obtained from this systematic
review will be influenced by the different designs of
included studies. Two reviewers will evaluate the quality
of evidence for our primary outcome (mortality) according
to five domains: study limitations, inconsistency of results,
indirectness of evidence, imprecision and reporting bias,
using the GRADE methodology [19]. We will report the
quality as very low, low, moderate or high.
Discussion
The rigorous systematic review methodology used for this
project will ensure the best available knowledge synthesis
on this topic. The internal peer-review and a priori sub-
mission of the protocol to PROSPERO will reduce the risk
of bias of this review and ensure a transparent process
throughout the project. The internal validation and pilot-
ing undertaken at every step of the review will decrease
the risk of selection bias and systematic extraction errors.
We will pilot and then use an evidence-based tool for
the evaluation of methodological quality and will use
the results for pre-specified subgroup analysis to explore
potential methodological cause for heterogeneity.
The results from a systematic review are dependent on
the quality of the underlying primary studies conducted.
For the current review, we are aware that most, if not all
studies will be cohort or case-control studies, and many
will be retrospective. As such, we decided purposively to
be very inclusive in our eligibility criteria so we can bet-
ter appraise the extent of the available literature as we
hypothesize that most of the evidence regarding the as-
sociation between donor characteristics and transfusion
outcomes may be of low methodological quality. Such a
comprehensive approach will allow us to assess the po-
tential impact of low-quality versus high-quality studies
on the estimation of the observed associations.
The results of this systematic review will provide the
best evidence regarding the potential clinical effects of
donor characteristics on transfusion recipients to better
guide policy and clinical practice. Our systematic review
will synthesize and update current knowledge regarding
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the results of our systematic review will identify clinical
and methodological strengths and weaknesses of existing
evidence regarding donor characteristics and recipient
outcome. It will serve as a foundation for further research
in the field and for the development of studies evaluating
present or establishing novel policies regarding outcome
improvement in transfusion medicine. The results of our
work will allow blood collection and supply organizations
to ensure that their current policies are evidence-based
and could result in updating national policies regarding
donor selection for blood transfusion. The potential opti-
mal identification of donor characteristics that are associ-
ated with better RBC transfusion outcome may ultimately
lead to an improvement in health outcomes in the trans-
fused patient population.
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